CO95 Growing Acceptance of Minimal Residual Disease (MRD) As a Primary Endpoint in Multiple Myeloma (MM) Clinical Trials

Jun 1, 2024, 00:00
10.1016/j.jval.2024.03.183
https://www.valueinhealthjournal.com/article/S1098-3015(24)00298-5/fulltext
Title : CO95 Growing Acceptance of Minimal Residual Disease (MRD) As a Primary Endpoint in Multiple Myeloma (MM) Clinical Trials
Citation : https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(24)00298-5&doi=10.1016/j.jval.2024.03.183
First page :
Section Title :
Open access? : No
Section Order : 11220
Categories :
Tags :
Regions :
ViH Article Tags :